Evommune (EVMN) Prepaid Assets (2024 - 2026)

Evommune (EVMN) reported Prepaid Assets of $4.4 million for Q1 2026, up 2.64% on a QoQ basis from $4.3 million in Q4 2025.

Evommune (EVMN) has 3 years of Prepaid Assets data on file, last reported at $4.4 million in Q1 2026.

  • Quarterly Prepaid Assets changed N/A year-over-year to $4.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.4 million (changed N/A YoY) and the FY2025 annual result came in at $4.3 million, up 119.61% from the prior year.
  • Prepaid Assets advanced to $4.4 million in Q1 2026 per EVMN's latest filing, from $4.3 million in the prior quarter.
  • Across five years, Prepaid Assets topped out at $5.9 million in Q3 2025 and bottomed at $1.9 million in Q4 2024.
  • The 3-year median for Prepaid Assets is $4.3 million (2025), against an average of $4.1 million.
  • Peak annual rise in Prepaid Assets reached 119.61% in 2025, while the deepest fall reached 119.61% in 2025.
  • Tracing EVMN's Prepaid Assets over 3 years: stood at $1.9 million in 2024, then surged by 119.61% to $4.3 million in 2025, then rose by 2.64% to $4.4 million in 2026.
  • Per Business Quant, the three latest EVMN Prepaid Assets figures stand at $4.4 million (Q1 2026), $4.3 million (Q4 2025), and $5.9 million (Q3 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Quantum Biopharma 1,216,509.61 Bn 1,216,509.61 Bn -
2 Alterity Therapeutics 764,224.41 Bn 764,224.38 Bn -
3 Legend Biotech 2,716.00 Bn 2,715.71 Bn 242.10 Mn
4 Nanobiotix 2,248.83 Bn 2,248.77 Bn -
5 Akari Therapeutics 1,951.18 Bn 1,951.17 Bn -
6 Vertex Pharmaceuticals 113.69 Bn 106.44 Bn 2.59 Bn
7 Evaxion A 64.16 Bn 64.14 Bn -
8 Regeneron Pharmaceuticals 63.94 Bn 55.18 Bn 3.31 Bn
9 Alnylam Pharmaceuticals 40.13 Bn 37.12 Bn 959.66 Mn
10 Evommune 782.16 Mn 570.69 Mn -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 4.39 Mn
Dec 31, 2025 4.28 Mn
Sep 30, 2025 5.88 Mn
Dec 31, 2024 1.95 Mn